2022³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-09-16±³À°ÀÏÀÚ : 2022-09-16
±³À°Àå¼Ò : ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
2022³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742
À̸ÞÀÏ :
secretariat@kcnp.or.kr ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 13 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø ¸éÁ¦/Á¤È¸¿ø 60,000¿ø/ºñȸ¿ø 70,000¿ø/ÁØȸ¿ø ¹× ±âŸ 40,000¿ø/´çÀϵî·Ïºñ Æò»ýȸ¿ø 10,000¿ø/Á¤È¸¿ø 80,000¿ø/ºñȸ¿ø 90,000¿ø/ÁØȸ¿ø ¹× ±âŸ 60,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 09:30~09:55 Aducanumab for dementia ¼½Â¿Ï(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 09:55~10:20 TAAR1 agonist for schizophrenia ¾çÂù¸ð(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 10:20~10:40 Orexin and daridorexant for sleep disorder ¾öÀ¯Çö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 09:30~09:55 Childbearing and pregnancy ±èµµÇö(´Ü±¹ÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 09:55~10:20 Liver disease ±è¿øÇü(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 10:20~10:40 Renal disease ½Åö¹Î(°í·ÁÀÇ´ë)
ÈÞ½Ä 09-16 10:40~10:55 ()
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 10:55~11:20 History of psychedelics: Ancient use È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 11:20~11:45 The psychedelic renaissance and the prohibition in 20C Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 11:45~12:10 Current researches and the future of psychedelics ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 10:55~11:20 Biological mechanism of neural plasticity and neurogenesis ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 11:20~11:45 Psychopharmacology of neural plasticity and neurogenesis ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 11:45~12:10 Non-psychopharmacological approach of neural plasticity and neurogenesis ±è³«¿µ(°è¿äº´¿ø)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 12:10~12:40 Is Zyprexa beneficial treatment for bipolar disorder ¼Á¤¼®(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 12:40~13:10 Role of Zyprexa in the treatment of schizophrenia ¹ÚÀÏÈ£(°¡Å縯°üµ¿ÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 12:10~12:40 MDD with mixed features: How to recognition and management with Aripiprazole in real clinical setting Á¤¿µÀº(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 12:40~13:10 Optimizing diagnosis and treatment for MDD with anxious distress ½ÉÀÎÈñ(µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø)
ÈÞ½Ä 09-16 13:10~13:30 ()
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 13:30~13:55 Clinical guideline for depressive disorder ¿ì¿µ¼·(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 13:55~14:20 Clinical guideline for bipolar disorder Á¤¸íÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 14:20~14:40 Clinical guideline for schizophrenia ÀÌÁ¤¼®(±¹¹Î°Ç°º¸ÇèÀϻ꺴¿ø)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 13:30~13:55 Cognitive decline in schizophrenia and its relation with dementia ¹Ú¼º¿ë(°è¿äº´¿ø)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 13:55~14:20 Polypharmacy in treating schizophrenia: Pros and cons °¿ø¼·(°æÈñÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 14:20~14:40 Recent findings of tardive dyskinesia ÀÌÁß¼±(¿ï»êÀÇ´ë)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 14:40~15:10 ADHD Ä¡·á¾à¹°·Î dextroamphetamineÀÇ ±¹³» µµÀÔÀº ÇÊ¿äÇÑ°¡? ½É¼¼ÈÆ/Àå¿ÁÁø(¼øõÇâÀÇ´ë/±¹¸³ºÎ°îº´¿ø)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 15:10~15:40 Telepsychiatry, Çã¿ëÇØ¾ß Çϳª? Á¤Çö°/ÀÓÀº¼º(°í·ÁÀÇ´ë/½Å¼¼°èÈ¿º´¿ø)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 14:40~15:10 What and why PCT and SDM? ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 15:10~15:40 How to practice PCT in psychiatry À̹®¼ö(°í·ÁÀÇ´ë)
ÈÞ½Ä 09-16 15:40~15:50 ()
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 15:50~16:15 Pathophysiology of hyperprolactinemia Á¤Çý°æ(°í·ÁÀÇ´ë »êºÎÀΰú)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 16:15~16:40 Endocrinological adverse effect of hyperprolactinemia ±èÇý¸®(¼Ãʼº¸ð Á¤½Å°Ç°ÀÇÇаú)
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 16:40~17:00 Clinical guideline for AAP-induced hyperprolactinemia ±è¼±¹Ì(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 15:50~16:15 Mobile digital technologies in monitoring mental disorders ¹éÁöÇö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 16:15~16:40 Mobile digital technologies in treating mental disorders ÇãÁö¿ø(°í·Á´ë ½É¸®Çаú)
±³À°½Ã°£ 09-16 ´ëȸÀÇ½Ç 16:40~17:00 Á¤½Å°Ç°ÀÇÇаú Áø·á¿¡¼ÀÇ wearable deviceÀÇ È°¿ë ÀüÈ«Áø(¼º±Õ°üÀÇ´ë)